CMTA has developed and validated a human iPSC-derived motor neuron assay for CMT2A in collaboration with ANANDA Devices and BrainXell. Now available through the CMTA-STAR Preclinical Toolbox, the platform enables parallel drug screening and direct visualization of mitochondrial mobility impairment in CMT2A patient-derived neurons.
CMTA Invests $141,000 to Study Hearing and Balance to Develop Better Clinical Trial Outcome Measures in Charcot-Marie-Tooth Disease
CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome measures in future CMT clinical trials.
CMTA Appoints David Stark, MD, and Catherine Illingworth to Board of Directors, Expanding Clinical and Biotech Expertise
CMTA welcomes David Stark, MD, and Catherine Illingworth to its Board of Directors, strengthening clinical insight and gene therapy leadership within the CMT community.
CMTA Addresses the Critical Delivery Challenge Underlying CMT Treatment Development through Four Key Investments
CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
CMTA Appoints Wendy Arnone as Board Chair
CMTA has appointed Wendy Arnone as board chair, succeeding Gilles Bouchard, who has led the board since 2016 and will continue serving as a board member. Arnone brings decades of executive healthcare leadership experience and a clinical background as a registered nurse, positioning her to guide CMTA’s continued investment in research and drug development for CMT.
CMTA-STAR Alliance Partner NMD Pharma Shares SYNAPSE-CMT Trial Update
New Phase 2a CMT trial results are in. NMD Pharma shares details.
When Early Testing Shows a Program Is Worth Continuing
Some research ideas reach a point where early testing answers an important question: Is this work worth continuing? For EverTree Bio, that moment came through early work using the CMTA Preclinical Toolbox.
CMTA Invests $100,000 in EverTree Bio to Support Cutting-Edge Therapeutic Research for CMT1A
CMTA announces a $100,000 investment in EverTree Bio to support continued development of an early-stage therapeutic program for CMT1A. The investment builds on early testing through the CMTA Preclinical Toolbox and reflects CMTA’s role in keeping strong CMT-focused research moving when it might otherwise stall.
ACT-CMT: The Largest-Ever Study of CMT Opens [Casting] Call for More Participants
The largest CMT1A study is expanding. New participants needed, including healthy volunteers. You can move this research forward.
Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles?
Can nanoparticles solve one of CMT’s largest hurdles? A team in Cyprus is testing nanoparticle “mail carriers” designed to deliver genetic therapies directly into Schwann cells.
